MX9701529A - 1,1,2-triphenylbut-1-ene derivatives for treating alzheimers disease. - Google Patents
1,1,2-triphenylbut-1-ene derivatives for treating alzheimers disease.Info
- Publication number
- MX9701529A MX9701529A MX9701529A MX9701529A MX9701529A MX 9701529 A MX9701529 A MX 9701529A MX 9701529 A MX9701529 A MX 9701529A MX 9701529 A MX9701529 A MX 9701529A MX 9701529 A MX9701529 A MX 9701529A
- Authority
- MX
- Mexico
- Prior art keywords
- triphenylbut
- alzheimers disease
- ene derivatives
- treating alzheimers
- methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention provides novel methods of inhibiting uterine fibrosis comprising administering to a mammal in need of such treatment an effective amount of a compound of formula 1 (see formula) wherein R1 and R2 may be the same or different provided that, when R1 and R2 are the same, each is a methyl or ethyl group, and, when R1 and R2 are different, one of them is a methyl or ethyl group and the other is hydrogen or a benzyl group; or a pharmaceutically acceptable salt thereof
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1241196P | 1996-02-28 | 1996-02-28 | |
US1240496P | 1996-02-28 | 1996-02-28 | |
US1240296P | 1996-02-28 | 1996-02-28 | |
US1240396P | 1996-02-28 | 1996-02-28 | |
US1240196P | 1996-02-28 | 1996-02-28 | |
US1241096P | 1996-02-28 | 1996-02-28 | |
US012402 | 1996-02-28 | ||
US012403 | 1996-02-28 | ||
US012401 | 1996-02-28 | ||
US012404 | 1996-02-28 | ||
US012410 | 1996-02-28 | ||
US012411 | 1996-02-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX9701529A true MX9701529A (en) | 1998-06-28 |
MXPA97001529A MXPA97001529A (en) | 1998-10-30 |
Family
ID=
Also Published As
Publication number | Publication date |
---|---|
CN1165651A (en) | 1997-11-26 |
EP0792640A2 (en) | 1997-09-03 |
JPH09328421A (en) | 1997-12-22 |
KR970061247A (en) | 1997-09-12 |
IL120268A0 (en) | 1997-06-10 |
EP0792640A3 (en) | 1998-07-08 |
AU707455B2 (en) | 1999-07-08 |
CA2198571A1 (en) | 1997-08-28 |
AU1495697A (en) | 1997-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY132056A (en) | Methods of inhibiting physiological conditions associated with an excess of neuropeptide y. | |
FI925342A0 (en) | Process for the preparation of therapeutically active (+) - - (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-piperidinemethanol | |
MX9803809A (en) | Biphenyl hydroxamate inhibitors of matrix metalloproteinases. | |
MY119375A (en) | Treatment of tinnitus using neuroprotective agents | |
RU94044436A (en) | Method of suppression of skin and vagina atrophy | |
UA41355C2 (en) | Agent for treating neuro-aids | |
GEP20043383B (en) | Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds | |
ZA948031B (en) | Methods of inhibiting uterine fibroses | |
RU94044453A (en) | Use of 2-phenyl-3-aroylbenzothiophenes for seborrhea and acne inhibition | |
ZA967880B (en) | Compositions and methods for inhibition of the patho-physiologic actions in mammals in tumor necrosis facto-alpha | |
RU94037233A (en) | Use of 2-phenyl-3-aroylbenzothiophenes for drug-resistant neoplasma treatment | |
CA2198580A1 (en) | Combination therapy to treat osteoporosis | |
MX9709466A (en) | Methods of inhibiting melanoma. | |
CA2289017A1 (en) | The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer | |
MY126321A (en) | Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer. | |
MX9701529A (en) | 1,1,2-triphenylbut-1-ene derivatives for treating alzheimers disease. | |
MX9701333A (en) | Methods for inhibiting neuronal damage. | |
MX9701606A (en) | Combination therapy to prevent bone loss- progesterone and strogen. | |
RU94044457A (en) | Use of benzthiophenes for hirsutism and alopecia inhibition | |
AU4944899A (en) | New pharmaceutically active compounds | |
MY113406A (en) | Methods of inhibiting physiological conditions associated with an excess of bradykinin | |
MX9604692A (en) | Quinoxaline derivatives for treating tinnitus. | |
MX9701528A (en) | 1,1,2-triphenylbut-1-ene derivatives for treating alzheimers disease. | |
MX9701532A (en) | Method of increasing testosterone. | |
RU94044487A (en) | Use of 2-phenyl-3-aroylbenzothiophenes for male sterility treatment |